Synthon: Zydus Lifesciences in pact with Synthon for specialty oncology product in US
Zydus Lifesciences has signed an exclusive agreement with Synthon for the development and commercialisation of a novel oncology product, focusing on reducing pill burden and improving patient compliance. Synthon will handle development and manufacturing, while Zydus will oversee NDA submission and marketing in the US by 2026.
Read full article »
Synthon is a Netherlands-based pharmaceutical company that develops, manufactures, and commercializes generic and hybrid medicines for patients.
Read more